Billions of US taxpayer dollars have been invested in Africa over the past 15 years to improve care for millions suffering from the HIV/AIDS epidemic; yet health systems on the continent continue to struggle. What if the investments and lessons learned from HIV could be used to improve care for those with other serious chronic conditions?
With this question in mind, researchers from Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center, along with investigators and clinicians based in Uganda, borrowed an HIV/AIDS innovation to seek inroads against rheumatic heart disease in sub-Saharan Africa.
Usually beginning as strep throat, if untreated, rheumatic heart disease can result in severe heart damage, even death. Monthly, long-term penicillin shots usually slow down its progression and reduce mortality. While largely eliminated in developed countries, rheumatic heart disease leads to over 320,000 deaths each year in Africa, the Middle East, Central and South Asia, and the South Pacific.
The borrowed tool, the HIV treatment-cascade, features a series of distinct, sequential steps for assessing supplied care. The Case Western-led team recently published a study of 1,500-plus patients in Circulation: Cardiovascular Quality and Outcome describing its use in combating rheumatic heart disease, one of the earliest attempts to adapt the model for another serious illness.
A central premise of the cascade is that if medical sites are broadly available and not confined to one location—usually a big city—patients will be more likely to comply with the demanding requirements that treatment can entail, whether taking several medications daily, as with AIDS, or tolerating recurrent needle injections, as with rheumatic heart disease.
In line with this premise, a chief finding of the new study is that difficulty getting to and from care was a more significant barrier to patient progress than either obtaining prescriptions for penicillin injections or patient-adherence to the monthly shot schedule. Of the 82 percent of patients who remained alive during the study, only 57 percent stayed in care for at least a year. But of those, more than 90 percent came for their shots at least nine months of the year. As expected, a key reason patients opted out of care was physical distance from a treatment center. But the researchers also found that for every kilometer closer they were to a health center, patients were six percent more likely to continue in care. Younger patient age and latent, as opposed to active disease status, were also strong independent predictors of patient retention and optimal adherence to care requirements.
"Patients in poorer nations who develop a chronic disease, whether it's AIDS, diabetes, or rheumatic heart disease, face similar obstacles to care," said the study's lead author, Chris Longenecker, MD, assistant professor of medicine at Case Western Reserve University School of Medicine. "We wanted to use the lessons learned in improving AIDS care to do the same for people living with rheumatic heart disease. As was true for people living with HIV in the early days, those living with rheumatic heart disease often have to come to the capital of Uganda, Kampala, for treatment. This means an expensive, five-to-six hour bus ride, assuming they even have the money to pay the fare. There are also the problems of poor roads, limited literacy, and bad weather during rainy season. But beginning in 2003, people living with HIV could get their treatments in health centers more widely dispersed throughout Uganda. We adopted this approach to help address rheumatic heart disease and our study confirms that it is effective. The message is clear: We need to take services to the people."
The ground work for the study was laid in 2012 when RHD Action Uganda, a collaboration of Case Western Reserve University School of Medicine, Children's National Medical Center (Washington, DC), and Makerere University, Uganda Heart Institute, Joint Clinical Research Center, Mbarara University of Science and Technology, and Gulu University School of Medicine—all from Uganda—was established with funding from the Medtronic Foundation. The program works to expand access to rheumatic heart disease care throughout the country. Core components include integrating rheumatic heart disease services into existing HIV/AIDS clinics and primary health care centers, establishing new regional care centers (four to date), training local health workers to deliver rheumatic heart disease services, and developing a national registry, which now keeps track of over 1,800 patients.
Because the new analysis adjusted for distance to the nearest health center, improved retention at regional sites is also likely attributable to more staff, funding, and ancillary resources per capita dedicated to tracking patients—resulting from the decision to decentralize care. Said Longenecker, "By offering care at the HIV/AIDS clinics, and establishing new care sites, we were able to dramatically increase care options for people living with RHD throughout the country. If efforts such as ours can be expanded throughout Africa, and low-income countries elsewhere, rheumatic heart disease can become a thing of the past in those places, as it has throughout the western world."
Explore further: Death rates from rheumatic heart disease falling since 1990
Chris T. Longenecker et al, Rheumatic Heart Disease Treatment Cascade in Uganda, Circulation: Cardiovascular Quality and Outcomes (2017). DOI: 10.1161/CIRCOUTCOMES.117.004037